Pamorelin LA 22.5 mg

Pamorelin LA 22.5 mg is a medicine authorised by Swissmedic under authorisation number 61238. The authorisation holder is Debiopharm Research & Manufacturing SA. The medicinal product code is Synthetic medicines and the dispensing category is A: Supplied only against a medical or veterinary prescription that may not be dispensed repeatedly. First authorisation was granted on 09 March 2011 and the authorisation is valid without a time limit. ATC code L02AE04 places the medicine in the group Endocrine therapy.

  • Dispensing category A
  • Authorisation number 61238
  • ATC L02AE04
  • Synthetic medicines
Authorisation data
Authorisation number61238
NamePamorelin LA 22.5 mg
Full namePamorelin LA 22.5 mg, poudre et solvant pour suspension injectable à libération prolongée
Authorisation holderDebiopharm Research & Manufacturing SA
Medicinal product codeSynthetic medicines
Dispensing categoryA · Prescription, not repeatable
ATC codeL02AE04
First authorisation09 March 2011
Authorisation validityunlimited
Strengths
No.NameDispensing categoryAuthorisation date
1Pamorelin LA 22.5 mg, poudre et solvant pour suspension injectable à libération prolongéeA09 March 2011
2Pamorelin LA 22.5 mg, poudre et solvant pour suspension injectable à libération prolongéeA07 September 2018

Scroll the table sideways

Pack sizes
Pack codeQuantityUnitATCIT codeDispensing category
11SetL02AE0407.16.2.A
21SetL02AE0407.16.2.A

Scroll the table sideways

Medicines in the same ATC group

Other medicines from this authorisation holder

Frequently asked questions

Is Pamorelin LA 22.5 mg authorised in Switzerland?

Yes. Pamorelin LA 22.5 mg is authorised by Swissmedic under authorisation number 61238, data as of 01 September 2026. The authorisation is valid without a time limit.

Which dispensing category does Pamorelin LA 22.5 mg have?

Pamorelin LA 22.5 mg is in dispensing category A. Supplied only against a medical or veterinary prescription that may not be dispensed repeatedly.

Who is the authorisation holder of Pamorelin LA 22.5 mg?

The authorisation holder is Debiopharm Research & Manufacturing SA. The holder carries the legal responsibility for quality, safety and product information of the medicine in Switzerland.

Sources

Swissmedic data as of 01 September 2026. No medical advice. Independent directory, not affiliated with Swissmedic or the FOPH.

Authorisation in Switzerland?

About 2 minutes. No obligation.

First, a little about your business.

Your answers stay in this page until you send your enquiry.

What would you like to achieve?

Your project

Where can we reach you?

You can go back to review your answers before sending.

* Required fields
Prefer email? info@swissmedicinesdirectory.com